These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24186317)

  • 1. Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.
    Díaz MQ; Borobia AM; Núñez MA; Virto AM; Fabra S; Casado MS; García-Erce JA; Samama CM
    Haematologica; 2013 Nov; 98(11):e143-4. PubMed ID: 24186317
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated prothrombin complex concentrate for dabigatran-associated bleeding.
    Schulman S; Ritchie B; Goy JK; Nahirniak S; Almutawa M; Ghanny S
    Br J Haematol; 2014 Jan; 164(2):308-10. PubMed ID: 24383848
    [No Abstract]   [Full Text] [Related]  

  • 3. Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.
    Wong H; Keeling D
    Br J Haematol; 2014 Jul; 166(1):152-3. PubMed ID: 24617554
    [No Abstract]   [Full Text] [Related]  

  • 4. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
    Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report.
    Faust AC; Peterson EJ
    J Emerg Med; 2014 Apr; 46(4):525-9. PubMed ID: 24508114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
    van Ryn J; Schurer J; Kink-Eiband M; Clemens A
    Anesthesiology; 2014 Jun; 120(6):1429-40. PubMed ID: 24714118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
    Dager WE; Gosselin RC; Roberts AJ
    Crit Care Med; 2013 May; 41(5):e42-6. PubMed ID: 23474679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.
    Dumkow LE; Voss JR; Peters M; Jennings DL
    Am J Health Syst Pharm; 2012 Oct; 69(19):1646-50. PubMed ID: 22997117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran.
    Murphy L; Lawler L; Kavanagh EC
    AJNR Am J Neuroradiol; 2011; 32(10):E195. PubMed ID: 22084193
    [No Abstract]   [Full Text] [Related]  

  • 11. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
    Alikhan R; Rayment R; Keeling D; Baglin T; Benson G; Green L; Marshall S; Patel R; Pavord S; Rose P; Tait C
    Emerg Med J; 2014 Feb; 31(2):163-8. PubMed ID: 23435652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal bleeding associated with dabigatran.
    Schaeffer S; Conway SE
    Am J Health Syst Pharm; 2013 Oct; 70(19):1651-2. PubMed ID: 24048598
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention and treatment of major bleeding during anticoagulation].
    Yasaka M; Okada Y
    Rinsho Shinkeigaku; 2013; 53(11):997-9. PubMed ID: 24291858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
    Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
    J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
    Berger R; Salhanick SD; Chase M; Ganetsky M
    Ann Emerg Med; 2013 Apr; 61(4):475-9. PubMed ID: 23522810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation.
    Levy JH
    Anesthesiology; 2014 Jun; 120(6):1316-8. PubMed ID: 24722175
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversal of a dabigatran overdose: what are possible options?
    Ratanapo S; Ungprasert P; Srivali N; Cheungpasitporn W; Bischof EF
    Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23974270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.